[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100474797":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":22,"locations":31,"responsibleParty":45,"collaborators":48,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Vanderbilt University Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants with Pulmonary Arterial Hypertension (PAH)",null,"Participants with heritable, idiopathic, and scleroderma associated PAH.",[13],"Other: No Intervention",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"No Intervention",[9],[19],{"name":20,"affiliation":5,"role":21},"Evan Brittain, MD, MSCI","PRINCIPAL_INVESTIGATOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Natasha Billard","CONTACT","(434) 851-3306","natasha.billard.1@vumc.org",{"name":20,"role":25,"phone":29,"phoneExt":10,"email":30},"(615) 322-4382","evan.brittain@vumc.org",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":10},"RECRUITING","Nashville","Tennessee","37232","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-86.78444,36.16589,{"lat":43,"lon":42},{"type":21,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Evan Brittain","Associate Professor of Medicine",[49],{"name":50,"class":51},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100474797","right-ventricle-lipid-in-pulmonary-arterial-hypertension-pah-100474797",false,"NCT05462574","Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)","Clinical and Mechanistic Understanding of Right Ventricular Steatosis in Pulmonary Arterial Hypertension (PAH)","Inclusion criteria:\n\n* ≥ 18 years old\n* Diagnosed with idiopathic, heritable, connective tissue disease-associated PAH, associated pulmonary arterial hypertension (PAH), or drug-or toxin-associated PAH according to World Health Organization (WHO) consensus recommendations.\n* Stable PAH-specific medication regimen for three months prior to enrollment. Adjustments in IV prostacyclin for side effect management are allowed. Diuretic adjustments are permitted.\n* WHO Functional Class I-III\n* Ambulatory\n* Able to have an MRI\u002FMRS, perform a 6MWD test, and cardiopulmonary exercise test\n\nExclusion criteria:\n\n* Pregnancy\n* Diagnosis of PAH etiology other than idiopathic, heritable, connective tissue disease - associated PAH or associated with drugs and toxins\n* WHO Functional class IV heart failure\n* Requirement for continuous oxygen\n* Unable to have an MRI\u002FMRS, perform a 6MWD test, or cardiopulmonary exercise test.\n* Patients with implanted\u002Fembedded ferromagnetic material that would preclude cardiac MRI","ALL","18 Years",{"count":62,"type":63},75,"ESTIMATED","OBSERVATIONAL","The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.",[67,68,69],"Idiopathic Pulmonary Arterial Hypertension","Heritable Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension Associated With Connective Tissue Disease","2026-05-26",{"date":72,"type":73},"2026-05-29","ACTUAL",{"date":75,"type":73},"2023-01-17",{"date":77,"type":63},"2027-09-30",{"name":5,"class":6},1]